AI
AXSM icon

Atom Investors’s Axsome Therapeutics AXSM Stock Holding History

Atom Investors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.38M Buy
+8,191
New +$1.41M 0.1% 305
2021
Q4 		– Sell
-19,098
Closed -$629K – 277
2021
Q3 		$629K Buy
+19,098
New +$744K 0.05% 175

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Atom Investors's AXSM Position: Q1 2026 in Review

Atom Investors opened a new position in Axsome Therapeutics (AXSM) in Q1 2026: 8,191 shares worth $1.38M. The stake represents 0.1% of the portfolio and ranks #305 among its holdings. This is a return to the name: Atom Investors previously reported a position in AXSM as recently as Q3 2021.

Atom Investors first reported a position in AXSM in Q3 2021 and has held it in 2 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Atom Investors held 8,191 shares of Axsome Therapeutics worth $1.38M as of Q1 2026.
  • Axsome Therapeutics was a new Atom Investors position in Q1 2026.
  • Axsome Therapeutics made up 0.1% of Atom Investors's portfolio in Q1 2026, its #305 holding.
  • Atom Investors first reported a position in Axsome Therapeutics in Q3 2021 and has held it in 2 quarters since.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Atom Investors's 13F filing for Q1 2026, filed 15 May 2026.